Anatara Lifesciences logo

ANR - Anatara Lifesciences Share Price

A$0.185 0.0  0.0%

Last Trade - 4:52am

Micro Cap
Market Cap £5.24m
Enterprise Value £3.72m
Revenue £n/a
Position in Universe 1659th / 1843
Unlock ANR Revenue
Relative Strength (%)
1m +7.73%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -58.9%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 30th Jun 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
0.20 2.80 3.15 0.40 0.66 0.000 6.00 11.5 -100.0%
Balance Sheet
FINANCIAL BRIEF: : For the fiscal year ended 30 June 2020, AnataraLifesciences Ltd revenues decreased from A$663K to A$0K.Net loss increased 17% to A$3.4M. Revenues reflect adecrease in demand for the Company's products and servicesdue to unfavorable market conditions. Higher net lossreflects Research and development expenses increase of 66%to A$1.3M (expense), R&D Expense - Tax Credit decrease of22% to A$660K (income).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History


ANR Revenue Unlock ANR Revenue

Net Income

ANR Net Income Unlock ANR Revenue

Normalised EPS

ANR Normalised EPS Unlock ANR Revenue

PE Ratio Range

ANR PE Ratio Range Unlock ANR Revenue

Dividend Yield Range

ANR Dividend Yield Range Unlock ANR Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
ANR EPS Forecasts Unlock ANR Revenue
Profile Summary

Anatara Lifesciences Ltd is an Australia-based company focused on developing oral solutions for gastrointestinal diseases in production animals and humans and the development and commercialization of Detach, a non-antibiotic therapy that prevents and treats diarrhea (scour) in piglets. Detach is a modified release formulation of BromelainRx, a natural extract from pineapple stems. Detach helps in address the overuse of antibiotics in animals. It is formulated with various ingredients to allow oral administration and delivery to the small intestine. The Company is focused on developing Detach for pigs in Australia and then expanding the program to Europe and the United States. The Company is also developing a similar version of Detach to prevent diarrhea in humans. The Company is seeking to collaborate with pharmaceutical/biotechnology companies for clinical development and commercialization of a similar version of Detach for human application in travelers and military personnel.

Last Annual June 30th, 2020
Last Interim June 30th, 2020
Incorporated July 15, 2010
Public Since October 16, 2014
No. of Shareholders: 1,020
No. of Employees: n/a
Sector Healthcare
Industry Biotechnology & Medical Research
Exchange Australian Stock Exchange - SEATS
Shares in Issue 49,856,177
Free Float (0.0%)
Eligible for
ANR Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for ANR
Upcoming Events for ANR
Frequently Asked Questions for Anatara Lifesciences
What is the Anatara Lifesciences share price?

As of 4:52am, shares in Anatara Lifesciences are trading at A$0.185, giving the company a market capitalisation of £5.24m. This share price information is delayed by 15 minutes.

How has the Anatara Lifesciences share price performed this year?

Shares in Anatara Lifesciences are currently trading at A$0.185 and the price has moved by -37.29% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Anatara Lifesciences price has moved by -35.75% over the past year.

What are the analyst and broker recommendations for Anatara Lifesciences?

Of the analysts with advisory recommendations for Anatara Lifesciences, there are there are currently 0 "buy" , 0 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Anatara Lifesciences is Buy. You can view the full broker recommendation list by unlocking its StockReport.

When will Anatara Lifesciences next release its financial results?

Anatara Lifesciences is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-06-30
What is the Anatara Lifesciences dividend yield?

Anatara Lifesciences does not currently pay a dividend.

Does Anatara Lifesciences pay a dividend?

Anatara Lifesciences does not currently pay a dividend.

When does Anatara Lifesciences next pay dividends?

Anatara Lifesciences does not currently pay a dividend.

How do I buy Anatara Lifesciences shares?

To buy shares in Anatara Lifesciences you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Anatara Lifesciences?

Shares in Anatara Lifesciences are currently trading at A$0.185, giving the company a market capitalisation of £5.24m.

Where are Anatara Lifesciences shares listed? Where are Anatara Lifesciences shares listed?

Here are the trading details for Anatara Lifesciences:

Country of listing: Australia
Exchange: ASX
Ticker Symbol: ANR
What kind of share is Anatara Lifesciences?

Based on an overall assessment of its quality, value and momentum, Anatara Lifesciences is currently classified as a Style Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Anatara Lifesciences share price forecast 2021?

Shares in Anatara Lifesciences are currently priced at A$0.185. At that level they are trading at 0.657% discount to the analyst consensus target price of 0.00.

Analysts covering Anatara Lifesciences currently have a consensus Earnings Per Share (EPS) forecast of 0.02 for the next financial year.

How can I tell whether the Anatara Lifesciences share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Anatara Lifesciences. Over the past six months, the relative strength of its shares against the market has been 11.62%. At the current price of A$0.185, shares in Anatara Lifesciences are trading at -4.74% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Anatara Lifesciences PE Ratio?

We were not able to find PE ratio data for Anatara Lifesciences.

Who are the key directors of Anatara Lifesciences?

Anatara Lifesciences's management team is headed by:

Michael West - COO
Sue MacLeman - NEC
Jane Ryan - NED
Steve Lydeamore - CEO
David Brookes - NED
Who are the major shareholders of Anatara Lifesciences?

Here are the top five shareholders of Anatara Lifesciences based on the size of their shareholding:

RTL Group Investments Pty. Ltd. Corporation
Percentage owned: 7.67% (5.40m shares)
Parma Corporation Pty. Ltd. Corporation
Percentage owned: 7.65% (5.39m shares)
TIGA Trading Pty Ltd Investment Advisor
Percentage owned: 7.56% (5.33m shares)
Myeng Pty. Ltd. Corporation
Percentage owned: 6.12% (4.31m shares)
Ross (Iain Gladstone) Individual Investor
Percentage owned: 2.27% (1.60m shares)
Similar to ANR
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.